ClinicalTrials.Veeva

Menu

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

Novartis logo

Novartis

Status and phase

Completed
Phase 3

Conditions

Major Depressive Disorder

Treatments

Drug: placebo
Drug: agomelatine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00411099
CAGO178A2301

Details and patient eligibility

About

This study will assess efficacy, safety and tolerability of agomelatine (AGO178) 25 mg and 50 mg in patients with Major Depressive Disorder (MDD). This study includes an 8-week double-blind phase and a 52-week open-label phase.

Enrollment

508 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of Major Depressive Disorder, single or recurrent episode, according to DSM-IV criteria
  • HAM-D17 total score > or = 22 at Screening and Baseline
  • CGI-Severity score > or = 4 at Screening and Baseline
  • Only patients who complete the core protocol are eligible to participate in the Open-Label Extension Phase

Exclusion criteria

  • History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating disorder, or obsessive compulsive disorder
  • Any current Axis I disorder other than major depressive disorder which is the focus of treatment
  • Substance or alcohol abuse in the last 30 days, dependence in the last 6 months
  • Concomitant psychotropic medication, including herbal preparations and melatonin
  • Psychotherapy of any type
  • Female patients of childbearing potential who are not using effective contraception

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

508 participants in 3 patient groups, including a placebo group

1
Experimental group
Treatment:
Drug: agomelatine
2
Experimental group
Treatment:
Drug: agomelatine
3
Placebo Comparator group
Treatment:
Drug: placebo

Trial contacts and locations

44

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems